Trial Profile
Tagraxofusp in Patients With CD123+ or With Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like Acute Myeloid Leukemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Tagraxofusp (Primary)
- Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm
- Focus Therapeutic Use
- Acronyms AML2020
- 12 Dec 2023 Results ( As of July 2023, n=23 ) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 20 Nov 2023 According to a Menarini media release, data from this study at the 65th American Society of Hematology (ASH) Annual Meeting 2023 December 11, 2023; 6:00 PM - 8:00 PM, San Diego Convention Center, Halls G-H
- 20 Nov 2023 According to a Menarini media release, data from this study will be presented at the San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.